Can Assertio give Zydus a faster route into U.S. specialty oncology care?
Zydus gets a U.S. oncology platform, but Rolvedon concentration risk will decide whether the Assertio deal becomes strategic or merely opportunistic.
Sentynl Therapeutics licenses Progerinin for progeria as rare-disease strategy expands beyond Zokinvy
Sentynl Therapeutics Inc., the United States-based rare disease subsidiary of Zydus Lifesciences Limited, has entered into a licensing agreement with South Korean biotechnology company PRG S&T to develop the investigational molecule Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome, an ultra-rare genetic disorder that causes accelerated aging in children. The therapy has received orphan drug designation from […]